Highlights in prostate cancer from the 2020 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 33006580 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 4, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Incorporating preemptive pharmacogenomic testing into the clinical setting.
Authors: O'Donnell PH PMID: 33006581 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 4, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Intratumoral HER2 heterogeneity in breast cancer.
Authors: Pegram M PMID: 33006582 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 4, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Chimeric antigen receptor natural killer cells for the treatment of patients with B-cell malignancies.
Authors: Rezvani K PMID: 33006583 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - October 4, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

PARP inhibition as frontline therapy in ovarian cancer.
Authors: Moore KN, Pothuri B, Monk B, Coleman RL Abstract Poly(ADP-ribose) polymerase (PARP) inhibitors have been rapidly integrated into clinical practice for women with ovarian cancer. Currently, PARP inhibitors are approved as frontline maintenance treatment for patients with and without BRCA-associated cancers, and they are listed by the National Comprehensive Cancer Network (NCCN) as a treatment option for all high-grade serous and endometrioid cancers with or without bevacizumab. PARP inhibitors are also approved as maintenance treatment following a response to platinum-based therapy in the recurrent setting,...
Source: Clinical Advances in Hematology and Oncology - October 4, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Immunotherapy for mesothelioma: rationale and new approaches.
Authors: Reuss JE, Forde PM Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 pathways has revolutionized the treatment of multiple malignancies and shown promise in mesothelioma, with multiple agents now recommended in the salvage setting for advanced disease progressive on platinum-based chemotherapy. Studies of frontline chemoimmunotherapy and ICB combinations have also been encouraging, and both are likely to...
Source: Clinical Advances in Hematology and Oncology - October 4, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Updated Recommendations for the Treatment of Immune Thrombocytopenia.
Authors: Cunningham JM PMID: 32903242 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Antibody-Drug Conjugates in Prostate Cancer.
Authors: Danila DC PMID: 32903243 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Optimizing the Use of Oral Therapy in Lymphoma.
Authors: Friedberg JW PMID: 32903244 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Chronic Lymphocytic Leukemia From the 2020 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 32903245 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Problem Solving to Enhance Clinical Trial Participation Utilizing a Framework-Driven Approach.
Authors: Lansey DG, Hefka TA, Carducci MA, Kanarek NF Abstract Health professionals agree that increasing diversity in clinical trial participants is an important way to improve cancer care and address disparities in outcomes. However, trial participation among minority populations has been low historically and continues to be low. Underrepresentation has resulted in majority groups reaping greater benefit from research findings, thus widening cancer health disparities. Addressing these disparities effectively has proven to be challenging. To maximize diversity among participants, it is necessary to understand the ...
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer.
Authors: Sharifi M, Wisinski KB Abstract The management of early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer has evolved in recent years, with the current standard being to tailor the intensity of adjuvant treatment to individual risk. Risk-adapted approaches to systemic therapy have been facilitated both by the recent introduction of multiple novel HER2-targeted therapies and by the development of clinical and pathologic surrogates to enable better prediction of disease behavior. These approaches have been successful at both ends of the disease spectrum. Patients with low-risk tum...
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Insights Into Drug Development Using Nanotechnology.
Authors: Grimm J PMID: 32903248 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

COVID-19 and Hypercoagulability.
Authors: Sholzberg M PMID: 32903249 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The Benefits of Reducing My Hours to Half-Time (That Is, Three-Quarter Time).
Authors: Muggia FM PMID: 32903250 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
Authors: Bishop MR PMID: 32903251 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Reversing Resistance to Checkpoint Inhibitors and Targeted Therapy in Metastatic Melanoma.
Authors: Sznol M PMID: 32903252 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia.
Authors: Akabane H, Logan A Abstract Measurable residual disease (MRD) quantification is an essential component of caring for patients with acute lymphoblastic leukemia (ALL). Many studies in pediatric and adult populations have validated the prognostic significance of MRD early in and throughout the course of treatment for ALL, and it is generally accepted that achievement of MRD less than 10[-4] (0.01%) is a critical milestone. ALL is uniquely amenable to quantification of MRD by multiple techniques, including multiparameter flow cytometry, various allele-specific and mutation-specific quantitative polymerase cha...
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Kidney Cancer.
Authors: PMID: 32903254 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - September 11, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in Aggressive Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 32720927 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in Aggressive Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting: Commentary.
Authors: Pagel JM PMID: 32720928 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Chronic Lymphocytic Leukemia From the 2019 American Society of Clinical Oncology Annual Meeting.
Authors: PMID: 32720929 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Chronic Lymphocytic Leukemia From the 2019 American Society of Clinical Oncology Annual Meeting: Commentary.
Authors: O'Brien SM PMID: 32720930 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community Physician.
Authors: Grothey A, Prager G, Yoshino T Abstract In 2012, the US Food and Drug Administration approved the kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-,oxaliplatin-, and irinotecan-based chemotherapy; an anti-vascular endothelial growth factor therapy; and, if RAS wild-type, an anti-epidermal growth factor receptor therapy. This approval brought a much-needed noncytotoxic chemotherapy treatment alternative to this heavily pretreated patient population. Initial phase 3 randomized clinical trials established an ove...
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Insights Into the Mechanism of Action of Regorafenib in Colorectal Cancer.
Authors: Grothey A PMID: 32720932 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Implications of the Mechanism of Action of Regorafenib for Clinical Practice.
Authors: Prager G PMID: 32720933 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Current and Future Research Into the Mechanism of Action of Regorafenib.
Authors: Yoshino T PMID: 32720934 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The Mechanism of Action of Regorafenib in Colorectal Cancer: Q & A.
The Mechanism of Action of Regorafenib in Colorectal Cancer: Q&A. Clin Adv Hematol Oncol. 2019 Aug;17 Suppl 12(8):16-19 Authors: Grothey A, Prager G, Yoshino T PMID: 32720935 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Authors: PMID: 32720923 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A Clinician's Perspective of Elotuzumab in the Treatment of Relapsed or Refractory Multiple Myeloma.
Authors: Richardson PG PMID: 32720924 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting.
Authors: PMID: 32720925 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting: Commentary.
Authors: Locke FL PMID: 32720926 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 30, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Advanced Prostate Cancer From the 2019 ASCO Genitourinary Cancers Symposium.
Authors: PMID: 32692734 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 24, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Advanced Prostate Cancer from the 2019 ASCO Genitourinary Cancers Symposium: Commentary.
Authors: George DJ PMID: 32692735 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 24, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on drugs in advanced ovarian cancer.
Authors: O'Malley D PMID: 32649652 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in CAR T-cell therapy for the treatment of multiple myeloma.
Authors: Shah N PMID: 32649653 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

EGFR inhibition in colorectal cancer with liver metastasis.
Authors: Grothey A PMID: 32649654 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The current status of secondary cytoreduction in ovarian cancer: a systematic review.
CONCLUSIONS: Secondary cytoreduction remains a viable treatment option for select patients for now, but this is entirely dependent on the highly anticipated overall survival results of DESKTOP III and SOC 1. PMID: 32649655 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Richter transformation of chronic lymphocytic leukemia in the era of novel agents.
Authors: Wang Y, Ding W Abstract The increased use of several effective novel targeted therapy agents has revolutionized therapy for patients with chronic lymphocytic leukemia (CLL). Disease progression in patients with CLL continues to occur, however. In particular, 3% to 25% of patients treated with a novel agent develop Richter transformation (RT); that is, histologic transformation of CLL to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). RT that develops in the novel agent era is frequently associated with adverse molecular alterations, such as TP53 disruption and complex karyotype...
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

CLL in focus.
Authors: Schuyler D PMID: 32628646 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Assessing the risk of heart failure in patients with acute leukemia.
Authors: Scherrer-Crosbie M PMID: 32628647 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma.
Authors: Zhang T, George DJ PMID: 32628648 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging role of immunotherapy in locally advanced non-small cell lung cancer.
Authors: Mulherkar R, Grewal AS, Berman AT Abstract Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to eluci...
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.
Authors: Laurence J Abstract Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) that is driven by uncontrolled activation of the alternative complement pathway, classically in the context of a genetic or autoimmune complement abnormality. Initial guidelines suggested lifelong treatment with the C5 inhibitor eculizumab, which until recently was the only therapy approved by the US Food and Drug Administration and European Medicines Agency for aHUS. However, multicenter observational studies provide compelling evidence that discontinuation of eculizumab, with careful monitoring for recurre...
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

COVID-19 in hem/onc news.
Authors: Schuyler D PMID: 32628651 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How we treat left-sided vs right-sided colon cancer.
Authors: Hanna DL, Lenz HJ PMID: 32628652 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Providing oncology care during the COVID-19 pandemic.
Authors: Lyman GH PMID: 32628653 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Strategies to overcome resistance to PD-1 inhibitors.
Authors: Gajewski TF PMID: 32628654 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Improving outcomes with checkpoint blockade in non-Hodgkin lymphoma.
Authors: Brody J PMID: 32628655 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in borderline resectable pancreatic adenocarcinoma.
Authors: Vadehra D, Salibi PN, McHaffie DR, Sulzer J, Iannitti DA, Hwang JJ Abstract Pancreatic adenocarcinoma is one of the most lethal cancers in oncology. Pancreatic cancer is the third most common cause of cancer-related mortality in the United States. As the years have progressed, the importance of a multidisciplinary and multimodal approach to pancreatic cancer care has been recognized and is now recommended in all major society guidelines. A subset of pancreatic cancer, borderline resectable pancreatic cancer (BRPC), has emerged as a distinct clinical entity for which specialized treatment plans are now bein...
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research